The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice

Acta Pharmacologica Sinica

Volumn 32, Issue 10, 2011, Pages 1253-1258

  Hu, Miao Miao ^a   Zhang, Jie ^a   Wang, Wen Yi ^a   Wu, Wen Yu ^a   Ma, Yan Ling ^a   Chen, Wei Hai ^b   Wang, Yi Ping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SOUTHWEST UNIVERSITY   (China)

Author keywords

atherosclerosis; darapladib; high sensitivity C reactive protein; inflammation; interleukin 6; LDLR deficient mice; lp PLA2; monocyte chemotactic protein 1; vascular cell adhesion molecule 1

Indexed keywords

BETA ACTIN; C REACTIVE PROTEIN; DARAPLADIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; AORTA ARCH; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; TREATMENT DURATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ATHEROSCLEROSIS; BENZALDEHYDES; C-REACTIVE PROTEIN; CHEMOKINE CCL2; ENZYME INHIBITORS; GENE DELETION; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; OXIMES; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80053921636     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.127     Document Type: Article

References (36)

1. Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 2009; 23: 49-59.
2. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-45.
3. Stafforini DM. Biology of platelet activating factor acetyhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009; 23: 73-83.
4. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Infamm Allergy Drug Discov 2008; 2: 72-6. (Pubitemid 351524324)
5. Miller RG, Costacou T, Orchard TJ. Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res 2010; 7: 47-55.
6. Wegner M, Araszkiewicz A, Piorunska-Mikolajczak A, Zozulinska-Ziolkiewicz D, Wierusz-Wysocka B, Piorunska-Stolzmann M. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem 2009; 42: 1621-7.
7. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-31. (Pubitemid 40627835)
8. Wang WY, Li J, Yang D, Xu W, Zha RP, Wang YP. OxLDL stimulates lipo-protein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res 2010; 85: 845-52.
9. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-87.
10. Leitinger N. Oxidized phospholipids as modulators of infammation in atherosclerosis. Curr Opin Lipidol 2003; 14: 421-30. (Pubitemid 37297296)
11. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3: 57-68. (Pubitemid 38234487)
12. Rong JX, Berman JW, Taubman MB, Fisher EA. Lysophos pha tidyl choline stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2002; 22: 1617-23.
13. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-82.
14. Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008; 51: 1632-41. (Pubitemid 351635837)
15. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-66.
16. Pinon P, Kaski JC. Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2, and cystatin C. New insights or redundant information? Rev Esp Cardiol 2006; 59: 247-58.
17. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-7. (Pubitemid 35373551)
18. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007; 27: 1706-21. (Pubitemid 47207165)
19. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-93. (Pubitemid 23262411)
20. Rosenson RS. Fenofibrate reduces lipoprotein associated phos pholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 2008; 155: 499.e9-16.
21. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-500. (Pubitemid 32493377)
22. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-55.
23. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110: 1903-8. (Pubitemid 39331899)
24. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Com munities (ARIC) study. Circulation 2004; 109: 837-42. (Pubitemid 38252734)
25. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1411-6. (Pubitemid 46823453)
26. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006; 152: 997-1003. (Pubitemid 44632932)
27. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26: 1586-93. (Pubitemid 44288987)
28. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006; 26: 2517-22. (Pubitemid 44607474)
29. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005; 2: 529-35. (Pubitemid 41670344)
30. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26: 137-44. (Pubitemid 40282781)
31. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phos pholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 527-32. (Pubitemid 43008525)
32. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med 2000; 162: 523-7. (Pubitemid 30647194)
33. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32: 332-41. (Pubitemid 38234108)
34. Liu J, Chen R, Marathe GK, Febbraio M, Zou W, McIntyre TM. Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase. Circ Res 2011; 108: 469-77.
35. Nonas S, Birukova AA, Fu P, Xing J, Chatchavalvanich S, Bochkov VN, et al. Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo. Crit Care 2008; 12: R27.
36. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90: 1138-44.